glp 1 bone loss GLP-1s may increase risk of osteoporosis and gout, new research finds GLP 1 drugs have been

future studies will shed light on whether semaglutide can compete (or synergize) with non-GLP-1 drugs like resmetirom (Madrigal, 30% resolution at 52 weeks), efuxifermin (Akero) and Lanifibranor (Inventiva) that are in late stage clinical testing for NASH

A stronger skin barrier means better moisture retention, reduced sensitivity, and improved protection against environmental stressors that accelerate the aging process

Mast cell activation and response to tolterodine in the rat urinary bladder in a chronic model of intravesical protamine sulfate and bacterial endotoxin-induced cystitis

Neurotransmitter System Interactions BPC-157 also touches the brain chemistry side of things